Level Biotechnology Inc.
Research Level Biotechnology Inc. (3118.TWO) on Bullrun: market cap TWD 999.55M, P/E 13.2, dividend yield 7.1%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker3118.TWO
- ExchangeTWO
- CountryTaiwan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyTWD
- Market capTWD 999.55M
- P/E13.2
- Dividend yield7.1%
- Financial periodQ2 2026
- RevenueTWD 162.35M
- Net incomeTWD 13.51M
- Free cash flowTWD 45.20M
- Gross margin33.9%
Valuation Snapshot
latest market cap is TWD 999.55M; P/E is 13.2; dividend yield is 7.1%.
Peer valuation comparison
Latest P/E is 13.22x versus a Healthcare sector median of 21.74x (39.2% below).
Latest dividend yield is 7.14% versus a Healthcare sector median of 2.4% (197.5% above).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | TWD 999.55M | 13.2 | 7.1% | 2.2 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 2.2 TWD, yield 7.1%.
About Level Biotechnology Inc.
Level Biotechnology Inc. engages in marketing and distributing cell culture, immunology, and molecular biology products in Taiwan. The company markets and distributes biomedical precision equipment. It also provides services in the areas of mammalian and genetic toxicology, pharmacology, biocompatibility, and model animal production. In addition, it offers preclinical research services to the biotech, pharmaceutical, medical device, animal health, and agrichemical industries.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Level Biotechnology Inc.'s market cap?
Level Biotechnology Inc.'s market capitalization is TWD 999.55M.
What is Level Biotechnology Inc.'s P/E ratio?
Level Biotechnology Inc.'s price-to-earnings (P/E) ratio is 13.2.
Does Level Biotechnology Inc. pay a dividend?
Level Biotechnology Inc. has a dividend yield of 7.1%.
What does Level Biotechnology Inc. do?
Level Biotechnology Inc. engages in marketing and distributing cell culture, immunology, and molecular biology products in Taiwan. The company markets and distributes biomedical precision equipment. It also provides services in the areas of mammalian and genetic toxicology, pharmacology, biocompatibility, and model animal production. In addition, it offers preclinical research services to the biotech, pharmaceutical, medical device, animal health, and agrichemical industries. The company was founded in 1989 and is headquartered in New Taipei City, Taiwan.